Navigation Links
Spherix Reports 2007 Financial Results
Date:4/3/2008

BETHESDA, Md., April 3, 2008 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) reported a net loss of $938,000 for the year ended December 31, 2007. The Company's research and development costs jumped to $5.9 million in 2007, from $884,000 in 2006, with the launch of the Company's Phase 3 clinical trial for Naturlose as a treatment for Type 2 diabetes in April 2007. The trial is expected to last at least two years, and will be financed through the proceeds received from the sale of the Company's InfoSpherix subsidiary. The Company's losses from continuing operations were $5.9 million and $700,000 for the years ended 2007 and 2006, which includes income tax benefit allocations of $3.4 million and $2.4 million each. Income from discontinued operations was $4.9 million and $4.2 million for each of the years ended 2007 and 2006, net of income tax expense allocations of $4.2 million and $2.5 million. Income from discontinued operations in 2007 included an $8.6 million pre-tax gain on the sale of our InfoSpherix subsidiary.

(Numbers in 000's)

2007 2006

Revenue $155 $7

Loss from continuing operations (5,851) (700)

Income from discontinued operations 4,913 4,213

Net (loss) income (938) 3,513

Net (loss) income per share

Continuing operations $ (0.41) $ (0.05)

Discontinued operations $ 0.35 $ 0.31

Net (loss) income per share $ (0.07) $ 0.26

Certain statements contained herein are "forward looking" statements as defined in
'/>"/>

SOURCE Spherix Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Spherix Reports 3rd Quarter Earnings
2. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
3. Genetic Engineering & Biotechnology News reports on cancer biomarkers
4. Derma Sciences Reports Fourth Quarter Year-End Results for 2007
5. China Bio Energy Reports Fiscal 2007 Financial Results
6. Laureate Pharma Reports Record Growth for 2007
7. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
8. PharmAthene Reports Year-End 2007 Financial Results
9. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
10. Photonic Products Group, Inc. Reports Record Financial Results for FY 2007
11. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... ... 2015 , ... Inc. Magazine released its annual list of the 5,000 fastest-growing ... growth for the three years through 2014. Being named to the Inc. 5000 list ... the country. , “We are thrilled to make the Inc. 5000 list for ...
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... in Personalized Medicine, recently presented new data on the relationship of genetics and ... 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, ...
(Date:8/26/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, today announced that ... & Company Emerging Growth Conference on September 2 at ... New York Marriott Marquis. A live ... investor relations section of Roka Bioscience,s website at ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3
... ... organic gardening simple, safe and fun. , ... Boston, MA (PRWEB) October 19, 2009 -- It,s no longer a complicated process ... matter of fact, "as the demand for healthy, fresh fruits and veggies grow, so has ...
... BEIJING, Oct. 19 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.,(OTC ... and,producer of prescriptions drugs and licensed national seller of pharmaceutical,products ... growth,strategy. , , Lotus,s priorities for the ... the Company needs to do for its most valuable customers, ...
... , EMERYVILLE, Calif., Oct. 19 Neurobiological Technologies, Inc. (Nasdaq: ... notice to the NASDAQ Stock Market LLC ("NASDAQ") that NTI ... Exchange Commission ("SEC") on or about October 28, 2009 to ... if NTI,s stockholders approve the dissolution of the company pursuant ...
Cached Biology Technology:The Growing Demand for Organic Gardening Sprouts New Self Sustaining Innovations 2The Growing Demand for Organic Gardening Sprouts New Self Sustaining Innovations 3Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy 2Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy 3Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy 4
(Date:8/5/2015)... Transparency Market Research has released ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... is forecast to reach US$ 2,671.8 Mn by 2022. ... systems by civil and government agencies. This is majorly ... activities across the globe that would elevate the demand ...
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... solutions, today announced that members of the executive management ... Pacific Crest Global Technology Leadership Forum on Tuesday, August ... will be held at the Sonnenalp Resort in ... presentation may include forward-looking information. An audio webcast of ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... 2008) -- Two major federal grants have been awarded to ... York City. Dr. Kenneth W. Griffin is the ... National Institute on Drug Abuse (NIDA) for research into the ... to urban minority youth attending New York City middle schools. ...
... 2008) The latest medications can delay the onset of ... effects. This limitation often makes early detection the key to ... long as possible. Now, a new device developed ... allow patients to take a brief, inexpensive test that could ...
... facing marine ecologists today, is just how much of an ... dispersal of larval and juvenile marine species from open oceans ... done through direct observation by divers on older larvae found ... the plankton. This method did not permit divers to follow ...
Cached Biology News:2 federal public health grants awarded to Weill Cornell Medical College 2Portable device quickly detects early Alzheimer's 2Portable device quickly detects early Alzheimer's 3How baby fish find a home 2
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
CD45/CD34 combination 50 tests...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: